Key Takeaways Axsome's Auvelity posted $215.9M in H1 2025 sales, which increased 82.3% year over year.AXSM plans to file an sNDA for Auvelity in the AD agitation later in the third quarter of 2025.Sunosi sales rose 25.6% in H1 2025, while Symbravo was launched in June after FDA approval.Axsome Therapeutics’ (AXSM) lead drug, Auvelity (AXS-05), approved for treating major depressive disorder, has witnessed strong sales uptake since its approval and launch. Auvelity, the first approved product in Axsome’s com ...